Long-term follow-up of 14 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia following autologous bone marrow transplantation in first complete remission

International Journal of Hematology

Volumn 85, Issue 2, 2007, Pages 140-145

  Mizuta, Shuichi ^a   Kohno, Akio ^b   Morishita, Yoshihisa ^b   Atsuta, Yoshiko ^c   Sao, Hiroshi ^d   Miyamura, Koichi ^e   Sakamaki, Hisashi ^f   Ueda, Ryuzo ^g   Morishima, Yasuo ^h  

^a FUJITA HEALTH UNIVERSITY HOSPITAL   (Japan)

^b JA Aichi Showa Hospital   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Meitetsu Hospital   (Japan)

^e JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^f TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^g NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^h AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Acute lymphoblastic leukemia; Autologous bone marrow transplantation; Ex vivo purging; Minimal residual disease; Philadelphia chromosome

Indexed keywords

BUSULFAN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; COMPLEMENT; CYCLOPHOSPHAMIDE; CYTARABINE; MELPHALAN; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; DEATH; FEMALE; FOLLOW UP; HUMAN; INTERSTITIAL PNEUMONIA; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; PHILADELPHIA 1 CHROMOSOME; PROBABILITY; QUANTITATIVE ANALYSIS; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; RECURRENCE; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS;

EID: 33847651870     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06104     Document Type: Article

References (24)

1. Hoelzer D, Gokbuget N. Recent approaches in acute lymphoblastic leukemia in adults. Crit Rev Oncol Hematol. 2000;36:49-58.
2. Lazarus HM, Rowe JM. Bone marrow transplantation for acute lymphoblastic leukemia (ALL). Med Oncol. 1994;11:75-88.
3. + ALL patients. Bone Marrow Transplant. 2003;31:623-632.
4. Morishima Y, Sao H, Ueda R, et al. Preliminary clinical trial of autologous bone marrow transplantation after in vitro monoclonal antibody and complement treatments in null cell-type acute lymphocytic leukemia. Jpn J Cancer Res. 1985;76:1222-1229.
5. Sao H, Morishima Y, Ueda R, et al. Serological study for in vitro use of monoclonal antibody for autologous bone marrow transplantation in null cell-type acute lymphocytic leukemia. Jpn J Cancer Res 1985;76:1212-1221.
6. Morishima Y, Miyamura K, Kojima S, et al. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement. Bone Marrow Transplant. 1993;11:255-259.
7. Mizuta S, Ito Y, Kohno A, et al, for the Nagoya BMT Group. Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation. Bone Marrow Transplant. 1999;24:777-784.
8. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547-561.
9. Barrett AJ, Horowitz MM, Ash RC, et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1992;79:3067-3070.
10. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 trial. Blood. 2002;100:2357-2366.
11. Stockschlader M, Hegewisch-Becker S, Kruger W, et al. Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant. 1995; 16:663-667.
12. Dunlop LC, Powles R, Singhal S, et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant. 1996;17:365-369.
13. Snyder DS. Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2000;6:597-603.
14. Mortuza FY, Papaioannou M, Moreira IM, et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20:1094-1104.
15. Bader P, Hancock J, Kreyenberg H, et al. Minimal residual disease status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia. 2002;16:1668-1672.
16. Radich J, Gehly G, Lee A, et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood. 1997;89:2602-2609.
17. Stirewalt DL, Guthrie KA, Beppu L, et al. Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. Biol Blood Marrow Transplant. 2003;9:206-212.
18. Towatari M, Yanada M, Usui N, et al, for the Japan Adult Leukemia Study Group. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood. 2004;104:3507-3512.
19. Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24:460-466.
20. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342:998-1006.
21. Snyder DS, Nademanee AP, O'Donnell MR, et al. Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia. 1999;13:2053-2058.
22. Deconinck E, Cahn JY, Milpied N, et al. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan). Bone Marrow Transplant. 1997;20:731-735.
23. Kroger N, Kruger W, Wacker-Backhaus G, et al. Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant. 1998;22:1029-1033.
24. Mineishi S, Longo WL, Atkinson ME, et al. Addition of high-dose AraC to the BMT conditioning regimen reduces leukemia relapse without an increase in toxicity. Bone Marrow Transplant. 1999;23:1217-1222.